Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)-Reference-Cited by-同舟云学术

Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

Published:2012-11-14 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bergner Nicole¹,Monsef Ina¹,Illerhaus Gerald²,Engert Andreas¹,Skoetz Nicole¹

Affiliation:

1. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany

2. University Hospital of Freiburg; Department I of Internal Medicine; Freiburg Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD009355.pub2/fullpdf

Reference40 articles.

1. Randomized phase II trial on primary chemotherapy with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARA-C) for patients with primary CNS lymphoma (PCNSL): The International Extranodal Lymphoma Study Group (IELSG) #20 Trial;Ferreri;Haematologica,2008

2. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial;Ferreri;Lancet,2009

3. Randomized phase II trial on primary chemotherapy with high-dose methotrexate alone or associated with high-dose cytarabine for patients with primary CNS lymphoma (IELSG #20 Trial): tolerability, activity and event-free survival analysis;Ferreri;Blood,2008

4. Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. # 20 Trial): tolerability, activity, and survival analyses [abstract no. 8545];Ferreri;Journal of Clinical Oncology,2009

5. Biology and treatment of primary central nervous system lymphoma;Algazi;Neurotherapeutics,2009

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis;Medicine;2023-07-07

2. Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma;Journal of Clinical Pharmacy and Therapeutics;2022-10-19

3. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series;Frontiers in Oncology;2022-06-16

4. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma;Journal of Clinical Medicine;2021-09-29

5. Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity;Current Oncology Reports;2021-09-15